• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Defining the Role of Donor Lymphocyte Infusion in High-Risk Hematologic Malignancies.

作者信息

Schmid Christoph, Kuball Jürgen, Bug Gesine

机构信息

Department of Hematology and Oncology, Augsburg University Hospital, Augsburg, Germany.

Department of Hematology and Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, the Netherlands.

出版信息

J Clin Oncol. 2021 Feb 10;39(5):397-418. doi: 10.1200/JCO.20.01719. Epub 2021 Jan 12.

DOI:10.1200/JCO.20.01719
PMID:33434060
Abstract
摘要

相似文献

1
Defining the Role of Donor Lymphocyte Infusion in High-Risk Hematologic Malignancies.明确供体淋巴细胞输注在高危血液系统恶性肿瘤中的作用
J Clin Oncol. 2021 Feb 10;39(5):397-418. doi: 10.1200/JCO.20.01719. Epub 2021 Jan 12.
2
Towards immunogene therapy of hematological malignancies.迈向血液系统恶性肿瘤的免疫基因治疗
Exp Hematol. 2006 Mar;34(3):251-63. doi: 10.1016/j.exphem.2005.10.004.
3
Invariant NKT Cells From Donor Lymphocyte Infusions (DLI-iNKTs) Promote Lysis of Leukemic Blasts in a CD1d-Dependent Manner.供者淋巴细胞输注中的不变自然杀伤 T 细胞（DLI-iNKT 细胞）以 CD1d 依赖性方式促进白血病原始细胞的裂解。
Front Immunol. 2019 Jul 9;10:1542. doi: 10.3389/fimmu.2019.01542. eCollection 2019.
4
Cellular immunotherapy after allogeneic stem cell transplantation in hematologic malignancies.血液系统恶性肿瘤异基因干细胞移植后的细胞免疫治疗。
Curr Opin Oncol. 2004 Mar;16(2):167-73. doi: 10.1097/00001622-200403000-00015.
5
Allogeneic cell-mediated immunotherapy at the stage of minimal residual disease following high-dose chemotherapy supported by autologous stem cell transplantation.在自体干细胞移植支持下的大剂量化疗后微小残留病阶段的异基因细胞介导免疫疗法。
Acta Haematol. 2005;114(4):214-20. doi: 10.1159/000088412.
6
Graft Versus Leukemia: Current Status and Future Perspectives.移植物抗白血病：现状与未来展望
J Clin Oncol. 2021 Feb 10;39(5):361-372. doi: 10.1200/JCO.20.01801. Epub 2021 Jan 12.
7
Adoptive immunotherapy:insights from donor lymphocyte infusions.过继性免疫疗法：来自供体淋巴细胞输注的见解。
Transfusion. 2000 Apr;40(4):393-5. doi: 10.1046/j.1537-2995.2000.40040393.x.
8
Minor histocompatibility antigens as targets of graft-versus-leukemia reactions.次要组织相容性抗原作为移植物抗白血病反应的靶点。
Curr Opin Hematol. 2002 Nov;9(6):497-502. doi: 10.1097/00062752-200211000-00005.
9
Donor lymphocyte infusion: the use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and nonmalignant diseases in conjunction with allogeneic stem cell transplantation.供体淋巴细胞输注：将同种异体反应性和肿瘤反应性淋巴细胞用于恶性和非恶性疾病的免疫治疗，并与异基因干细胞移植联合使用。
J Hematother Stem Cell Res. 2002 Apr;11(2):265-76. doi: 10.1089/152581602753658457.
10
Immunotherapy of hematological malignancies with dendritic cells.利用树突状细胞对血液系统恶性肿瘤进行免疫治疗。
Hematol J. 2004;5 Suppl 3:S96-9. doi: 10.1038/sj.thj.6200431.

引用本文的文献

1
Exercise-mobilized donor lymphocyte infusions enhanced with cytokine stimulation for the prevention and treatment of leukemic relapse after allogeneic hematopoietic cell transplantation.通过细胞因子刺激增强运动动员的供体淋巴细胞输注，用于预防和治疗异基因造血细胞移植后的白血病复发。
Front Immunol. 2025 Jun 12;16:1563972. doi: 10.3389/fimmu.2025.1563972. eCollection 2025.
2
Current use of donor lymphocyte infusions after allogenic stem cell transplantation in Europe: a survey on behalf of the cellular therapy and immunobiology working party of the EBMT.欧洲异基因干细胞移植后供体淋巴细胞输注的当前应用情况：代表欧洲血液与骨髓移植协会细胞治疗与免疫生物学工作组开展的一项调查
Bone Marrow Transplant. 2025 May;60(5):697-701. doi: 10.1038/s41409-025-02555-9. Epub 2025 Mar 23.
3
Utility of the 2024 best practice recommendations from the EBMT Cellular Therapy and Immunobiology Working Party for use of donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation.欧洲血液与骨髓移植协会（EBMT）细胞治疗与免疫生物学工作组2024年关于异基因造血干细胞移植后供体淋巴细胞输注应用的最佳实践建议的效用。
Bone Marrow Transplant. 2025 Feb;60(2):247-249. doi: 10.1038/s41409-024-02458-1. Epub 2024 Nov 15.
4
Genetically modified and unmodified cellular approaches to enhance graft versus leukemia effect, without increasing graft versus host disease: the use of allogeneic cytokine-induced killer cells.利用同种异体细胞因子诱导的杀伤细胞增强移植物抗白血病效应而不增加移植物抗宿主病：基因修饰和未修饰的细胞方法。
Front Immunol. 2024 Oct 24;15:1459175. doi: 10.3389/fimmu.2024.1459175. eCollection 2024.
5
Beneficial effects of cellular immunotherapy in the prevention and treatment of posttransplant hematologic relapse of myelodysplastic neoplasms.细胞免疫疗法在预防和治疗骨髓增生异常综合征移植后血液学复发中的有益作用。
Ann Hematol. 2024 Dec;103(12):5261-5272. doi: 10.1007/s00277-024-06060-9. Epub 2024 Nov 6.
6
Maintenance Therapy Post-Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia.急性髓系白血病造血干细胞移植后的维持治疗。
Curr Oncol. 2024 Oct 10;31(10):6050-6060. doi: 10.3390/curroncol31100451.
7
Cell-Based Treatment in Acute Myeloid Leukemia Relapsed after Allogeneic Stem Cell Transplantation.异基因造血干细胞移植后复发的急性髓系白血病的细胞治疗
Biomedicines. 2024 Aug 1;12(8):1721. doi: 10.3390/biomedicines12081721.
8
Chimeric Antigen Receptor (CAR) T-Cell Therapy in Hematologic Malignancies: Clinical Implications and Limitations.嵌合抗原受体（CAR）T细胞疗法在血液系统恶性肿瘤中的应用：临床意义与局限性
Cancers (Basel). 2024 Apr 22;16(8):1599. doi: 10.3390/cancers16081599.
9
Expanding the repertoire reveals recurrent, cryptic, and hematopoietic HLA class I minor histocompatibility antigens.扩展抗原库揭示了反复出现的、隐匿的和造血的 HLA Ⅰ类次要组织相容性抗原。
Blood. 2024 May 2;143(18):1856-1872. doi: 10.1182/blood.2023022343.
10
Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: immune escape mechanisms and current implications for therapy.异基因造血干细胞移植后急性髓系白血病的复发：免疫逃逸机制及目前对治疗的影响。
Mol Cancer. 2023 Nov 11;22(1):180. doi: 10.1186/s12943-023-01889-6.